Australia's TGA pathway for imported medical cannabis

Why this is worth understanding before any commercial conversation

Every patient prescribed medical cannabis in Australia depends on a chain of professionals who each carry liability — the prescriber, the dispensing pharmacist, the distributor, the licensed importer. The chain only holds if the regulatory pathway and the supply documentation align. That's the part most "we can supply Australia" pitches skim past.

If you're a licensed Australian importer evaluating a Thai supplier, the relevant question isn't "do they have export approval?" — it's "will their paperwork survive a TGA query, an internal audit, or a patient adverse-event review?" Those three pressures shape every requirement below.

What is the TGA pathway for medical cannabis?

The Therapeutic Goods Administration (TGA) regulates how medicines reach Australian patients. Medical cannabis is treated as an "unapproved therapeutic good" — not registered on the Australian Register of Therapeutic Goods (ARTG), but legally accessible to patients through one of two prescriber-driven schemes:

1. Special Access Scheme Category B (SAS-B) — the prescriber submits a per-patient notification to the TGA, identifying the specific product, dose, indication, and rationale. Most cannabis prescriptions in Australia today flow through this route.
2. Authorised Prescriber (AP) scheme — the prescriber applies once for category-level approval to prescribe an unapproved good for a defined indication and patient cohort. After approval, no per-patient notifications are required — the AP simply prescribes and reports periodically.

Both pathways require the underlying product to be:

• Manufactured under conditions equivalent to Australian GMP (or imported under an authorisation that accepts the foreign GMP regime)
• Documented per-batch with a Certificate of Analysis covering cannabinoids, terpenes, microbial limits, residual solvents, heavy metals, and pesticide residues
• Delivered through a TGA-licensed importer / sponsor who maintains traceability

The patient never sees this paperwork. The pharmacist might glance at a CoA. The TGA can demand the entire chain — including cultivation records — within 24 hours during a compliance review.

SAS-B in practice — what the prescriber files

A SAS-B notification names the specific cannabis product (brand, strain, cannabinoid profile), the indication, the patient's clinical history, and the prescriber's reasoning. The TGA acknowledges the notification — they don't approve it in the registration sense — and the prescription can proceed.

For an importer, this means the product specification you supply must be stable enough to be named in a notification that follows the patient on their medical record. Strain swaps, batch-level profile drift, or unannounced potency changes break that link. A TGA reviewer comparing a notification from January against a CoA from June expects the cannabinoid ratio to be within reasonable assay variance — not "we changed the genetics that quarter."

Authorised Prescriber — and why it raises the documentation bar

An AP-scheme prescriber doesn't need to notify per patient, but they're accountable for product consistency across their patient cohort. Many APs require their licensed importer to commit to:

• A defined cultivar (genetic line) for the duration of the approval
• A cannabinoid-ratio tolerance band (typically ±10–15% of the labelled value)
• Certificate of Analysis per shipment, with retained samples for at least the prescribed shelf life
• Notification of any change to cultivation site, drying/curing protocol, or post-harvest processing

These aren't TGA-mandated requirements per se — they're risk-management terms the AP imposes on their supply contract. An exporter who cannot meet them in writing will not earn AP-channel business, regardless of price.

What licensed importers verify before stocking a Thai supplier

In our experience supplying Australian importers, the documentation requested before contract signing falls into four buckets:

Cultivation foundation

• TH-GACP certification (Thailand's Good Agricultural and Collection Practices for medicinal plants). Cultivation-level. We've written separately on what TH-GACP actually means.
• Department of Thai Traditional and Alternative Medicine licence numbers
• Cultivation site audit report (third-party where possible)
• Pesticide-use logs and chemistry inputs disclosure

Post-harvest manufacture

• GMP-equivalent processing facility certification
• Drying, curing, and storage protocols, including humidity / temperature logs
• Trim and packaging procedures with batch separation evidence

Per-batch quality

• ISO/IEC 17025 third-party Certificate of Analysis covering: cannabinoids (Δ9-THC, THCA, CBD, CBDA, CBN, CBG, minor cannabinoids), full terpene profile, microbiological limits (TAMC, TYMC, E. coli, Salmonella, Aspergillus), residual solvents, heavy metals (Pb, As, Cd, Hg), pesticide residues, mycotoxins
• Retained samples per batch, stored at the manufacturer's facility for the documented shelf life

Chain-of-custody

• Export licence and CITES paperwork where applicable
• Temperature-controlled freight documentation (we cover why container temperature matters separately)
• Importer-receipt CoA (a re-test on arrival in Australia is increasingly common)

This is roughly the standard supply pack a serious importer asks for before signing. If a Thai supplier can't produce items 1–4 within a single business week, they're not export-ready — they're export-curious.

What this means for patients

The reason these requirements exist is not bureaucratic — it's that an Australian patient holding a prescription for "5g of CBD-dominant flower at 8% CBD / <0.3% THC" needs that flower to actually be that flower. Strain drift means dose drift means therapeutic-window drift. A patient with refractory epilepsy whose CBD ratio quietly shifts mid-supply is not a paperwork problem; it's a clinical event.

Every line item on an Australian importer's documentation request reduces the probability of that clinical event. The TGA wrote the rules in patient-protection language because that's what they protect.

How CannaBless fits the pathway

We supply Australian licensed importers because the regulatory pathway above describes the kind of supplier we want to be — one whose documentation survives any reasonable scrutiny on the receiving side.

Concretely, every CannaBless export packet includes:

• Current TH-GACP certification with site identifier
• Cultivation, drying, curing, and post-harvest protocol summary
• ISO/IEC 17025 CoA per batch (full panel)
• Cultivar genetic record with cannabinoid-ratio tolerance band
• Cold-chain documentation from packing through container handover
• A named single point of contact for compliance questions, in business hours UTC+7

If you're a licensed Australian importer evaluating Thai supply, the export desk replies within one business day. The conversation usually starts with a question we welcome: "show us the documentation pack."

That's the right question. Patients depend on it.